Ivosidenib - Agios Pharmaceuticals

Drug Profile

Ivosidenib - Agios Pharmaceuticals

Alternative Names: AG 120

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Cholangiocarcinoma
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 11 Dec 2017 Interim efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Agios Pharmaceuticals
  • 11 Dec 2017 Agios Pharmaceuticals completes enrolment in its phase I/II trial for Acute myeloid leukaemia (Combination therapy, First-line therapy) in Australia, Canada, Italy, South Korea, Netherlands, Spain, France, Germany, Switzerland, United Kingdom, Portugal and USA (PO) before December 2017
  • 17 Nov 2017 Interim efficacy and adverse events data from a phase I trial in Solid tumours released by Agios Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top